Equities

BrightGene Bio-Medical Technology Co Ltd

688166:SHH

BrightGene Bio-Medical Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)24.28
  • Today's Change-0.56 / -2.25%
  • Shares traded4.63m
  • 1 Year change+13.19%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,0221,202334
Total Receivables, Net382372412
Total Inventory345280200
Prepaid expenses615039
Other current assets, total31348.10
Total current assets1,8401,938993
Property, plant & equipment, net2,5272,1801,490
Goodwill, net7.507.507.50
Intangibles, net948281
Long term investments488399348
Note receivable - long term------
Other long term assets------
Total assets5,0324,6612,970
LIABILITIES
Accounts payable188217208
Accrued expenses737261
Notes payable/short-term debt197160261
Current portion long-term debt/capital leases41431526
Other current liabilities, total504826
Total current liabilities922812583
Total long term debt1,6361,582619
Total debt2,2472,057907
Deferred income tax------
Minority interest495063
Other liabilities, total562626
Total liabilities2,6632,4701,291
SHAREHOLDERS EQUITY
Common stock422422410
Additional paid-in capital1,0571,008739
Retained earnings (accumulated deficit)898743555
Treasury stock - common------
Unrealized gain (loss)(84)(57)--
Other equity, total7575(26)
Total equity2,3692,1921,678
Total liabilities & shareholders' equity5,0324,6612,970
Total common shares outstanding422422410
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.